First human trial offers hope for rare, fatal nerve disease

NCT ID NCT02362438

Summary

This is a first-in-human safety study testing a new gene therapy for Giant Axonal Neuropathy (GAN), a rare and fatal genetic disorder that damages nerves. Researchers are giving a single spinal injection that delivers a working copy of the faulty gene to the brain and spinal cord. The study aims to see if this treatment is safe and if it can slow or stop the progression of the disease in children and adults.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT AXONAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States

Conditions

Explore the condition pages connected to this study.